Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Mei-Jing Liu, Kai-Wen Tan, Han-Yu Cao, Si-Man Huang, Chong-Sheng Qian, Sheng-Li Xue, Hai-Ping Dai, Wen-Jie Gong
No abstract text is available yet for this article.
February 2024: HemaSphere
#22
Gaetano Celardo, Elena Scaffei, Bianca Buchignani, Graziella Donatelli, Mauro Costagli, Paola Cristofani, Raffaello Canapicchi, Rosa Pasquariello, Michela Tosetti, Roberta Battini, Laura Biagi
Chemotherapy and radiotherapy are widely used in the treatment of central nervous system tumors and acute lymphocytic leukemia even in the pediatric population. However, such treatments run the risk of a broad spectrum of cognitive and neurological deficits. Even though the correlation with cognitive decline is still not clear, neuroradiological defects linked to white matter injury and vasculopathies may be identified. Thanks to the use of 7T MRI it is possible to better define the vascular pattern of the brain lesions with the added advantage of identifying their characteristics and anatomical localization, which, however, are not evident with a conventional brain scan...
2024: Frontiers in Neurology
#23
REVIEW
Susan Branford, Adelina Fernandes, NurHezrin Shahrin, Muneeza Maqsood, Naranie Shanmuganathan, Carol Wadham
Chronic myeloid leukemia (CML) is a model of genomically based diagnosis and management where BCR::ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) therapy in most patients. The dynamics of BCR::ABL1 transcript decline during therapy is a dependable biomarker of response, relapse, and drug resistance. Missense mutations acquired within the BCR::ABL1 kinase domain that disrupt TKI binding can evolve during therapy and are frequently detected in patients for whom TKI treatment fails. Importantly, specific BCR::ABL1 missense mutations are targetable alterations and direct therapeutic decisions based on the individual mutant TKI sensitivity profile...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
#24
JOURNAL ARTICLE
Abdulrhman S Elbnnani, Mohamed Elbasir, Salah Altabal, Yosra Lamami, Fawzi Ebrahim, Hakema M Oshah, Rasem Alagnef, Adam Elzagheid, Abdulmunem M Abulayha
The diagnosis of acute lymphoblastic leukemia (ALL), which is the most common type of cancer in children, has become more accurate with the use of flow cytometry. Here, this technology was used to immunophenotype leukemic cells in peripheral blood samples from Libyan pediatric ALL patients. We recruited 152 newly diagnosed patients at Tripoli Medical Center (Tripoli, Libya) by morphological examination of blood and bone marrow. Twenty-three surface and cytoplasmic antigen markers were used to characterize B and T cells in circulating blood cells by four-color flow cytometry...
December 31, 2024: Libyan Journal of Medicine
#25
JOURNAL ARTICLE
Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani, Hervé Ghesquières, Gerardo Musuraca, Francesca Gaia Rossi, Francesco Merli, Romain Guièze, Emmanuel Gyan, Guido Gini, Dario Marino, Remy Gressin, Franck Morschhauser, Federica Cavallo, Francesca Palombi, Annarita Conconi, Benoît Tessoulin, Hervé Tilly, Manuela Zanni, Maria Giuseppina Cabras, Enrico Capochiani, Catello Califano, Melania Celli, Alessandro Pulsoni, Francesco Angrilli, Ubaldo Occhini, René-Olivier Casasnovas, Guillaume Cartron, Liliana Devizzi, Corinne Haioun, Anna Marina Liberati, Roch Houot, Michele Merli, Giuseppe Pietrantuono, Francesca Re, Michele Spina, Francesco Landi, Franco Cavalli, Francesco Bertoni, Davide Rossi, Nicoletta Ielmini, Elena Borgo, Stefano Luminari, Emanuele Zucca, Catherine Thieblemont
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment with chlorambucil plus rituximab. Study treatment comprised an induction phase with chlorambucil 6 mg/m2/day orally on weeks 1-6, 9-10, 13-14, 17-18, and 21-22, and rituximab 375 mg/m2 intravenously on day 1 of weeks 1-4, and 1400 mg SC on weeks 9, 13, 17, and 21...
February 22, 2024: Haematologica
#26
JOURNAL ARTICLE
Syed Mohd Adnan Naqvi, Sk Najrul Islam, Abhishek Kumar, Chandrahas Ramchandra Patil, Ajay Kumar, Absar Ahmad
Acute lymphoblastic leukemia (ALL), a hematologic cancer that involves the production of abnormal lymphoid precursor cells, primarily affects children aged 2 to 10 years. The bacterial enzyme L-asparaginase produced from Escherichia coli is utilised as first-line therapy, despite the fact that 30 % of patients have a treatment-limiting hypersensitivity reaction. The current study elucidates the biosynthesis of extremely stable, water-dispersible, anisotropic Ag nanoparticles at room temperature and investigation of its anti-tumor potency in comparison to L-asparaginase...
February 15, 2024: International Journal of Biological Macromolecules
#27
JOURNAL ARTICLE
Zhaohua Zhang, Chuan Sun, Lingyi Cai, Ying Chen, Xinyi Zhou, Suipeng Chen, Xiao Feng, Xiangchou Yang, Qian Li, Lihua Liu, Haixia Zhou, Baoqing Li
BACKGROUND: Philadelphia chromosome-positive acute myeloid leukemia (Ph+ AML) is a rare leukemia subtype first classified by the World Health Organization in 2016. The incidence of Ph+ AML is approximately 0.5 - 3%, and its prognosis is poor. Ph+ AML with additional chromosomal abnormalities in children has rarely been reported, and its treatment and prognosis remain uncertain. METHODS: We retrospectively analyzed 649 patients with AML from 2006 - 2021. Six (0.9%) patients with Ph+ AML were identified and treated with conventional chemotherapy...
February 1, 2024: Clinical Laboratory
#28
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Phosphoinositide 3-kinase gamma (PI3Kγ) is implicated as a target to repolarize tumor-associated macrophages and promote anti-tumor immune responses in solid cancers. However, cancer cell-intrinsic roles of PI3Kγ are unclear. Here, by integrating unbiased genome-wide CRISPR interference screening with functional analyses across acute leukemias, we define a selective dependency on the PI3Kγ complex in a high-risk subset that includes myeloid, lymphoid, and dendritic lineages. This dependency is characterized by innate inflammatory signaling and activation of phosphoinositide 3-kinase regulatory subunit 5 ( PIK3R5 ), which encodes a regulatory subunit of PI3Kγ and stabilizes the active enzymatic complex...
December 15, 2023: bioRxiv
#29
Sahar Khosravi, Khatereh Mousavi-Fatemi, Pouyan Ebrahimi, Mohammad Barary, Terence T Sio, Ali Tavakoli Pirzaman
Few cases of B-cell acute lymphoblastic leukemia (B-ALL)-eosinophilia (ALL-eo) association have been reported. The lack or absence of blasts in the peripheral blood smear (PBS) along with urticarial rash, fever, arthralgia, myalgia, sweating, and dyspnea are common features of this condition. Herein, we report a 16-year-old male patient admitted to the emergency department with urticaria and generalized itching. PBS was examined, and eosinophils (90%) were seen in different fields. However, blast cells were not seen in PBS...
2024: SAGE Open Medical Case Reports
#30
JOURNAL ARTICLE
Andrew J Menssen, Chad A Hudson, Todd Alonzo, Robert Gerbing, Laura Pardo, Amanda Leonti, Jacqueline A Cook, Fan-Chi Hsu, Loren L Lott, Fangyan Dai, Collette Fearing, Keely Ghirardelli, Tiffany Hylkema, Katherine Tarlock, Keith R Loeb, Edward A Kolb, Todd Cooper, Jessica Pollard, Denise A Wells, Michael R Loken, Richard Aplenc, Soheil Meshinchi, Lisa Eidenschink Brodersen
As curative therapies for pediatric AML remain elusive, identifying potential new treatment targets is vital. We assessed the cell surface expression of CD74, also known as the MHC-II invariant chain, by multidimensional flow cytometry in 973 patients enrolled in the Children's Oncology Group AAML1031 clinical trial. 38% of pediatric AML patients expressed CD74 at any level and a comparison to normal hematopoietic cells revealed a subset with increased expression relative to normal myeloid progenitor cells...
February 1, 2024: Haematologica
#31
JOURNAL ARTICLE
Li Zhang, Xiao Liu, Shuai Zhou, Peng Wang, Xuan Zhang
Acute lymphoblastic leukemia (ALL) is a devastating hematological malignancy characterized by uncontrolled proliferation of immature lymphoid cells. While advances in treatment have improved patient outcomes, challenges remain in enhancing therapeutic efficacy and understanding underlying molecular mechanisms. Methyltransferase-like 7B (METTL7B), known for its methyltransferase activity, has been implicated in various solid tumors, yet its role in ALL remains unexplored. Here, we reveal that high METTL7B expression is correlated with poorer prognosis in ALL patients...
January 31, 2024: Human Cell
#32
REVIEW
Jonathan Paolino, Harrison K Tsai, Marian H Harris, Yana Pikman
IKZF1 encodes the transcription factor IKAROS, a zinc finger DNA-binding protein with a key role in lymphoid lineage development. IKAROS plays a critical role in the development of lineage-restricted mature lymphocytes. Deletions within IKZF1 in B-cell acute lymphoblastic leukemia (B-ALL) lead to a loss of normal IKAROS function, conferring leukemic stem cell properties, including self-renewal and subsequent uncontrolled growth. IKZF1 deletions are associated with treatment resistance and inferior outcomes...
January 1, 2024: Biomedicines
#33
REVIEW
Rosario M Morales-Camacho, Teresa Caballero-Velázquez, Juan José Borrero, Ricardo Bernal, Concepción Prats-Martín
Eosinophils in peripheral blood account for 0.3-5% of leukocytes, which is equivalent to 0.05-0.5 × 109 /L. A count above 0.5 × 109 /L is considered to indicate eosinophilia, while a count equal to or above 1.5 × 109 /L is defined as hypereosinophilia. In bone marrow aspirate, eosinophilia is considered when eosinophils make up more than 6% of the total nuclear cells. In daily clinical practice, the most common causes of reactive eosinophilia are non-hematologic, whether they are non-neoplastic (allergic diseases, drugs, infections, or immunological diseases) or neoplastic (solid tumors)...
January 12, 2024: Cancers
#34
JOURNAL ARTICLE
Dilshad Alghazzawi, Aqsa Noor, Hanan Alolaiyan, Hamiden Abd El-Wahed Khalifa, Alhanouf Alburaikan, Songsong Dai, Abdul Razaq
Cancer is characterized by uncontrolled cell proliferation, leading to cellular damage or death. Acute lymphoblastic leukemia (ALL), a kind of blood cancer, that affects lymphoid cells and is a challenging malignancy to treat. The Fermatean fuzzy set (FFS) theory is highly effective at capturing imprecision due to its capacity to incorporate extensive problem descriptions that are unclear and periodic. Within the framework of this study, two innovative aggregation operators: The Fermatean fuzzy Dynamic Weighted Averaging (FFDWA) operator and the Fermatean fuzzy Dynamic Weighted Geometric (FFDWG) operator are presented...
January 22, 2024: Scientific Reports
#35
JOURNAL ARTICLE
Y Jiao, Y H Jiang, B Liu, R H Mi, L J Bi, Q X Xu
Objective: To compare and analyze the clinical characteristics of acute myeloid leukemia (AML) related to the treatment of hematological tumors and solid tumors. Methods: The laboratory and clinical data of 41 patients with treatment-related AML (t-AML) in the Department of Hematology, Henan Cancer Hospital from January 2014 to December 2021 were retrospectively analyzed, and they were divided into hematological tumor group and solid tumor group. Survival analysis was performed using the Kaplan-Meier method and Log rank test...
January 23, 2024: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
#36
Derek H Janssens, Melodie Duran, Dominik J Otto, Danielle Kirkey, Joanna S Yi, Soheil Meshinchi, Jay F Sarthy, Kami Ahmad, Steven Henikoff
Chromosomal translocations involving the Lysine-Methyl-Tansferase-2A ( KMT2A ) locus generate potent oncogenes that cause highly aggressive acute leukemias 1 . KMT2A and the most frequent translocation partners encode proteins that interact with DNA to regulate developmental gene expression 2 . KMT2A-oncogenic fusion proteins (oncoproteins) contribute to the epigenetic mechanisms that allow KMT2A -rearranged leukemias to evade targeted therapies. By profiling the oncoprotein-target sites of 34 KMT2A -rearranged leukemia samples, we find that the genomic enrichment of oncoprotein binding is highly variable between samples...
December 30, 2023: bioRxiv
#37
Andy G X Zeng, Ilaria Iacobucci, Sayyam Shah, Amanda Mitchell, Gordon Wong, Suraj Bansal, Qingsong Gao, Hyerin Kim, James A Kennedy, Mark D Minden, Torsten Haferlach, Charles G Mullighan, John E Dick
Initial classification of acute leukemia involves the assignment of blasts to cell states within the hematopoietic hierarchy based on morphological and immunophenotypic features. Yet, these traditional classification approaches lack precision, especially at the level of immature blasts. Single-cell RNA-sequencing (scRNA-seq) enables precise determination of cell state using thousands of markers, thus providing an opportunity to re-examine present-day classification schemes of acute leukemia. Here, we developed a detailed reference map of human bone marrow hematopoiesis from 263,519 single-cell transcriptomes spanning 55 cellular states...
December 27, 2023: bioRxiv
#38
JOURNAL ARTICLE
Min Feng, Bailing Zhang, Guilan Li, Yan Yang, Jiangyuan Liu, Ziting Zhang, Bing Zhou, Han Zhang
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive subtype of ALL characterized by its high heterogeneity and unfavorable clinical features. Despite improved insights in genetic and epigenetic landscapes of T-ALL, the molecular mechanisms that drive malignant T-cell development remain unclear. BTB and CNC homology 2 (BACH2) is a lymphoid-specific transcription repressor recognized as a tumor suppressor in B-cell malignancies, but little is known about its function and regulatory network in T-ALL. Here we found extremely low levels of BACH2 in T-ALL clinical samples and cell lines compared to normal T cells...
January 17, 2024: Cell Death & Disease
#39
JOURNAL ARTICLE
Fan Yang, Bo Zhang, Paul Lodder, Jing Guo
PURPOSE: Acute lymphoblastic leukemia (ALL) is a type of blood cancer that affects white blood cells. Here, we use data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, to estimate the burden and incidence rate changes in adolescents and young adults (AYA) ALL in the Western Pacific Region and to reveal potential risk factors of incidence- and mortality rates. METHODS: The GBD 2019 study data was stratified by sex, age, country, and territory...
January 16, 2024: Cancer Causes & Control: CCC
#40
REVIEW
Ugo Testa, Simona Sica, Elvira Pelosi, Germana Castelli, Giuseppe Leone
Treatment of refractory and relapsed (R/R) B acute lymphoblastic leukemia (B-ALL) is an unmet medical need in both children and adults. Studies carried out in the last two decades have shown that autologous T cells engineered to express a chimeric antigen receptor (CAR-T) represent an effective technique for treating these patients. Antigens expressed on B-cells, such as CD19, CD20, and CD22, represent targets suitable for treating patients with R/R B-ALL. CD19 CAR-T cells induce a high rate (80-90%) of complete remissions in both pediatric and adult R/R B-ALL patients...
2024: Mediterranean Journal of Hematology and Infectious Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
